Genmab A/S Sponsored ADR (GMAB) - What Are Brokerages Thinking About This Stock?

Key Points

• Analyst sentiment is moderately bullish: Genmab has a “Moderate Buy” consensus from 13 brokerages, with nine buys, three holds and one strong buy. The average 12-month price target is $43.39.
• Shares have rallied strongly, opening at $43.79 near their 12-month high of $44.34, compared with 50-day and 200-day moving averages of $35.25 and $30.23, respectively.
• Genmab exceeded quarterly expectations, reporting earnings of $0.54 per share versus the $0.37 consensus and revenue of $1.16 billion versus estimates of $1.12 billion. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) has been given an average rating of "Moderate Buy" by the thirteen brokerages that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $43.39.

A number of research analysts have commented on GMAB shares. New Street Research set a $43.00 price target on Genmab A/S in a research report on Wednesday, July 22nd. TD Cowen upgraded Genmab A/S from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $32.00 to $43.00 in a research report on Wednesday, July 22nd. Truist Financial upped their target price on Genmab A/S from $40.00 to $45.00 and gave the company a "buy" rating in a report on Wednesday, October 7th. Morgan Stanley set a $42.00 target price on Genmab A/S in a report on Tuesday, October 20th. Finally, Guggenheim upped their target price on Genmab A/S from $45.00 to $54.00 and gave the stock a "buy" rating in a report on Monday, October 5th.

Institutional Trading of Genmab A/S

Hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC lifted its position in Genmab A/S by 26.4% during the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company's stock valued at $118,442,000 after acquiring an additional 921,700 shares during the period. First Trust Advisors LP boosted its position in shares of Genmab A/S by 84.3% in the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company's stock worth $66,038,000 after purchasing an additional 1,126,069 shares in the last quarter. Quantinno Capital Management LP boosted its position in shares of Genmab A/S by 14.4% in the 1st quarter. Quantinno Capital Management LP now owns 282,498 shares of the company's stock worth $7,579,000 after purchasing an additional 35,588 shares in the last quarter. Royal Bank of Canada boosted its position in shares of Genmab A/S by 1.8% in the 1st quarter. Royal Bank of Canada now owns 150,135 shares of the company's stock worth $4,029,000 after purchasing an additional 2,637 shares in the last quarter. Finally, Legacy Wealth Asset Management LLC increased its position in Genmab A/S by 164.1% during the 2nd quarter. Legacy Wealth Asset Management LLC now owns 102,164 shares of the company's stock valued at $2,806,000 after buying an additional 63,484 shares in the last quarter. Institutional investors own 7.07% of the company's stock.

Genmab A/S Stock Performance

NASDAQ GMAB opened at $43.79 on Monday. The company's 50 day moving average is $35.25 and its 200-day moving average is $30.23. The firm has a market cap of $27.33 billion, a P/E ratio of 34.48, a price-to-earnings-growth ratio of 2.01 and a beta of 0.81. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. Genmab A/S has a 12-month low of $23.62 and a 12-month high of $44.34.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.17. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.12 billion. Sell-side analysts predict that Genmab A/S will post 1.22 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab's marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.